株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腫瘍アブレーションの世界市場の予測 (〜2021年):技術 (高周波・マイクロ波・冷凍・IRE・超音波・レーザー)・治療モード・対象疾患別

Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound, Laser), Mode of Treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) - Global Forecast 2021

発行 MarketsandMarkets 商品コード 335087
出版日 ページ情報 英文 261 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
腫瘍アブレーションの世界市場の予測 (〜2021年):技術 (高周波・マイクロ波・冷凍・IRE・超音波・レーザー)・治療モード・対象疾患別 Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound, Laser), Mode of Treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) - Global Forecast 2021
出版日: 2016年10月05日 ページ情報: 英文 261 Pages
概要

世界の腫瘍アブレーションの市場は2016年から2021年にかけて12.5%のCAGR (年間複合成長率) で推移し、2021年には5億8010万米ドルの規模に成長すると予測されています。現在は北米、欧州の成熟市場が最大のシェアを占めているものの、今後はアジア太平洋地域が最大の成長を遂げると予測されています。有効性や安全性の強化に焦点を当てた技術的発展、最小侵襲性技術への需要の拡大、世界的な癌患者数の増加、R&Dを支援する官民のイニシアチブや資金供給の拡大などが、同市場の成長を促す要因となっています。

当レポートでは、世界の腫瘍アブレーションの市場を調査し、市場および技術の概要、産業構造とバリューチェーン、市場成長への各種影響因子および市場機会の分析、技術・治療モード・対象疾患別の動向および市場規模の推移と予測、地域および主要国の動向、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 市場機会
  • 北米:最大の地域シェア
  • 中国・インド:予測期間中の市場成長を主導
  • 中国・インド:マイクロ波・冷凍アブレーション製品の需要を推進する見通し
  • 肝臓癌:最大の対象疾患別シェア
  • MEDTRONIC:市場の中心的位置付け

第5章 腫瘍アブレーションの世界市場:概要

  • イントロダクション
  • 市場の発展の推移
  • 市場力学
    • 影響分析
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 腫瘍アブレーションの世界市場:産業分析

  • イントロダクション
  • バリューチェーン分析
  • 産業動向
  • ポーターのファイブフォース分析

第7章 腫瘍アブレーションの世界市場:技術別

  • イントロダクション
  • 高周波アブレーション
  • マイクロ波アブレーション
  • 冷凍アブレーション
  • その他

第8章 腫瘍アブレーションの世界市場:治療モード別

  • イントロダクション
  • 外科的アブレーション
  • 腹腔鏡下アブレーション
  • 経皮的アブレーション

第9章 腫瘍アブレーションの世界市場:対象疾患別

  • イントロダクション
  • 肝臓癌
  • 肺癌
  • 腎臓癌
  • 骨転移腫瘍
  • その他

第10章 腫瘍アブレーションの世界市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • イタリア
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • その他
  • その他

第11章 競合環境

  • イントロダクション
  • 市場シェア分析
  • 競合シナリオ
  • 近年の発展動向
    • パイプライン開発・製品の強化
    • 投資撤退・買収
    • 地域的拡張
    • 合意・提携・協力
    • その他

第12章 企業プロファイル

  • イントロダクション
  • ANGIODYNAMICS, INC.
  • BOSTON SCIENTIFIC CORPORATION
  • GALIL MEDICAL, INC.
  • EDAP TMS S.A.
  • HEALTHTRONICS, INC. (ALTARIS CAPITAL PARTNERS, LLC)
  • MEDTRONIC PLC
  • MERMAID MEDICAL, INC.
  • MISONIX, INC.
  • NEUWAVE MEDICAL, INC. (ETHICON - J&J GROUP OF COMPANY)
  • SONACARE MEDICAL, LLC

第13章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MD 3271

The global tumor ablation market is estimated to register a high CAGR of 12.5% during 2016-2021, and is expected to be valued at ~USD 580.1 million in 2021. Although mature markets (North America and Europe) held large shares of the tumor ablation market in 2016, the Asia-Pacific region is projected to register the highest growth during the next five years. A number of factors such as technological advancements in the field of tumor ablation focused on enhancing effectiveness and safety of the treatment, rising demand of minimal invasive tumor ablation techniques, increasing prevalence of cancer across the globe, and growing public-private initiatives and funding to support R&D activities in tumor ablation are propelling the growth of the market. However, factors such as unfavorable regulatory policies and cost-containment measures adopted by various governments are restraining the optimal market growth.

On the basis of technology, the global tumor ablation market is divided into four major categories, namely, radiofrequency ablation, microwave ablation, cryoablation, and others (includes electrical, laser/light, ultrasound). Based on mode of treatment, the tumor ablation market is segmented into surgical mode, laparoscopic mode, and percutaneous mode. On the basis of application of tumor ablation, the market is categorized into liver cancer, lung cancer, kidney/renal cancer, bone metastasis, and others (includes tumor ablation for the treatment of prostate, breast, colorectal, thyroid, pancreas, neuroendocrine, head, neck, and lumbar-vertebra cancer).

Geographically, North America is estimated to command the largest share of the global tumor ablation market in 2016, followed by Europe. The high prevalence and incidence of major types of cancer (such as liver, lung, kidney, and bone metastasis) in the region, rising inclination of patients towards minimally invasive procedures for cancer treatment, and increasing government funding for cancer research are market drivers in North America. However, unsupportive government policies, limited availability of medical reimbursements in the U.S., and cost-containment measures adopted by governments in the U.S. and Canada are negatively affecting the growth of the tumor ablation market in this region.

The tumor ablation market is fairly competitive, with a large number of global and local manufacturers of tumor ablation solutions. Medtronic plc (Ireland), AngioDynamics, Inc. (U.S.), and HealthTronics, Inc. (U.S.) were the top three players in the tumor ablation market in 2015. New product launches and product enhancements; acquisitions; geographic expansions; and partnerships, agreements, and collaborations are the major strategies adopted by most players to achieve growth in the tumor ablation market.

Benefits of Buying the Report:

This report studies tumor ablation market based on technologies, modes of treatment, and applications. The report also studies, factors (such as drivers, restraints, opportunities, and challenges) which positively and negatively affect market growth. It analyzes opportunities and challenges in the market for stakeholders, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes the micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. GEOGRAPHIC SCOPE
    • 1.3.3. YEARS CONSIDERED FOR THE STUDY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. KEY DATA FROM SECONDARY SOURCES
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. KEY DATA FROM PRIMARY SOURCES
  • 2.2. OPPORTUNITY INDICATORS
    • 2.2.1. DEMAND-SIDE ANALYSIS
    • 2.2.2. SUPPLY-SIDE ANALYSIS
  • 2.3. MARKET SIZE ESTIMATION
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5. RESEARCH ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT MARKET SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. MARKET OPPORTUNITIES FOR GROWTH IN TUMOR ABLATION MARKET (2016-2021)
  • 4.2. NORTH AMERICA TO COMMAND THE LARGEST SHARE OF TUMOR ABLATION MARKET FOR ALL MODES OF TREATMENT (2016)
  • 4.3. CHINA AND INDIA TO LEAD THE MARKET GROWTH FOR TUMOR ABLATION TECHNOLOGIES DURING THE FORECAST PERIOD
  • 4.4. CHINA AND INDIA TO LEAD THE MARKET DEMAND FOR MICROWAVE AND CRYOABLATION-BASED TUMOR ABLATION PRODUCTS (2016-2021)
  • 4.5. LIVER CANCER HOLDS THE LARGEST SHARE IN TUMOR ABLATION MARKET IN 2016
  • 4.6. MEDTRONIC, PLC DOMINATED THE TUMOR ABLATION MARKET IN 2015

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET EVOLUTION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. IMPACT ANALYSIS
    • 5.3.2. KEY MARKET DRIVERS
      • 5.3.2.1. RISING PREVALENCE OF CANCER
      • 5.3.2.2. TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF THERMAL ABLATION
      • 5.3.3.3. RISING MARKET DEMAND FOR MINIMALLY INVASIVE SURGERIES
      • 5.3.3.4. INCREASING PUBLIC-PRIVATE FUNDING FOR PRODUCT DEVELOPMENT AND COMMERCIALIZATION
      • 5.3.3.5. GROWING NUMBER OF HOSPITALS AND SURGICAL & ABLATION CENTERS
    • 5.3.3. KEY MARKET RESTRAINTS
      • 5.3.3.1. UNFAVORABLE REGULATORY SCENARIO
      • 5.3.3.2. COST-CONTAINMENT MEASURES ADOPTED BY VARIOUS REGIONAL GOVERNMENTS
    • 5.3.4. KEY MARKET OPPORTUNITIES
      • 5.3.4.1. IMPROVING HEALTHCARE INFRASTRUCTURE ACROSS EMERGING COUNTRIES
      • 5.3.4.2. INCREASING PATIENT AWARENESS ABOUT THE THERAPEUTIC BENEFITS OF TUMOR ABLATION
      • 5.3.4.3. EVOLVING REIMBURSEMENT SCENARIO
    • 5.3.5. KEY MARKET CHALLENGES
      • 5.3.5.1. THERAPEUTIC CHALLENGES RELATED TO TUMOR ABLATION PROCEDURES

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. INDUSTRY TRENDS
    • 6.3.1. GROWING ADOPTION RATE OF RADIOFREQUENCY-BASED TUMOR ABLATION PROCEDURES
    • 6.3.2. GROWING MARKET FOCUS ON THE DEVELOPMENT OF NOVEL MICROWAVE-BASED TUMOR ABLATION PRODUCTS
  • 6.4. PORTER'S FIVE FORCE ANALYSIS
    • 6.4.1. OVERVIEW
    • 6.4.2. THREAT FROM NEW ENTRANTS
    • 6.4.3. THREAT OF SUBSTITUTES
    • 6.4.4. BARGAINING POWER OF SUPPLIERS
    • 6.4.5. BARGAINING POWER OF BUYERS
    • 6.4.6. INTENSITY OF COMPETITIVE RIVALRY

7. TUMOR ABLATION TECHNOLOGY MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. RADIOFREQUENCY (RF) ABLATION
  • 7.3. MICROWAVE ABLATION
  • 7.4. CRYOABLATION
  • 7.5. OTHER TECHNOLOGIES

8. TUMOR ABLATION TECHNOLOGY MARKET, BY MODE OF TREATMENT

  • 8.1. INTRODUCTION
  • 8.2. SURGICAL ABLATION
  • 8.3. LAPAROSCOPIC ABLATION
  • 8.4. PERCUTANEOUS ABLATION

9. TUMOR ABLATION TECHNOLOGY MARKET, BY APPLICATION

  • 9.1. INTRODUCTION
  • 9.2. LIVER CANCER ABLATION
  • 9.3. LUNG CANCER ABLATION
  • 9.4. KIDNEY CANCER ABLATION
  • 9.5. BONE METASTASIS ABLATION
  • 9.6. OTHER APPLICATIONS

10. TUMOR ABLATION TECHNOLOGY MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. ITALY
    • 10.3.2. GERMANY
    • 10.3.3. FRANCE
    • 10.3.4. U.K.
    • 10.3.5. SPAIN
    • 10.3.6. REST OF EUROPE (ROE)
  • 10.4. ASIA-PACIFIC
    • 10.4.1. JAPAN
    • 10.4.2. CHINA
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA-PACIFIC (ROAPAC)
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. MARKET SHARE ANALYSIS, BY KEY PLAYER (2015)
  • 11.3. COMPETITIVE SCENARIO
  • 11.4. RECENT DEVELOPMENTS
    • 11.4.1. PIPELINE DEVELOPMENTS AND PRODUCT ENHANCEMENTS
    • 11.4.2. DIVESTMENTS AND ACQUISITIONS
    • 11.4.3. GEOGRAPHIC EXPANSION
    • 11.4.4. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 11.4.5. OTHER DEVELOPMENTS

12. COMPANY PROFILES

  • 12.1. INTRODUCTION
    • 12.1.1. GEOGRAPHIC BENCHMARKING
    • 12.1.2. KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS
  • 12.2. ANGIODYNAMICS, INC. (U.S.)
    • 12.2.1. COMPANY OVERVIEW
    • 12.2.2. MNM VIEW
    • 12.2.3. ANGIODYNAMICS, INC.-COMPANY SNAPSHOT
    • 12.2.4. PRODUCT PORTFOLIO
    • 12.2.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.3. BOSTON SCIENTIFIC CORPORATION (U.S)
    • 12.3.1. COMPANY OVERVIEW
    • 12.3.2. MNM VIEW
    • 12.3.3. BOSTON SCIENTIFIC CORPORATION-COMPANY SNAPSHOT
    • 12.3.4. PRODUCT PORTFOLIO
    • 12.3.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.4. GALIL MEDICAL, INC. (U.S.)
    • 12.4.1. COMPANY OVERVIEW
    • 12.4.2. MNM VIEW
    • 12.4.3. BTG INTERNATIONAL LTD.- COMPANY SNAPSHOT
    • 12.4.4. PRODUCT PORTFOLIO
    • 12.4.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.5. EDAP TMS S.A. (FRANCE)
    • 12.5.1. COMPANY OVERVIEW
    • 12.5.2. EDAP TMS S.A.-COMPANY SNAPSHOT*
    • 12.5.3. PRODUCT PORTFOLIO
    • 12.5.4. RECENT DEVELOPMENTS (2013-2016)
  • 12.6. HEALTHTRONICS, INC. (U.S.) [A BUSINESS SEGMENT OF ALTARIS CAPITAL PARTNERS, LLC (U.S.)]
    • 12.6.1. COMPANY OVERVIEW
    • 12.6.2. MNM VIEW
    • 12.6.3. PRODUCT PORTFOLIO
    • 12.6.4. RECENT DEVELOPMENTS (2013-2016)
  • 12.7. MEDTRONIC PLC (IRELAND)
    • 12.7.1. COMPANY OVERVIEW
    • 12.7.2. MNM VIEW
    • 12.7.3. MEDTRONIC PLC-COMPANY SNAPSHOT
    • 12.7.4. PRODUCT PORTFOLIO
    • 12.7.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.8. MERMAID MEDICAL, INC. (DENMARK)
    • 12.8.1. COMPANY OVERVIEW
    • 12.8.2. PRODUCT PORTFOLIO
    • 12.8.3. RECENT DEVELOPMENTS (2013-2016)
  • 12.9. MISONIX, INC. (U.S)
    • 12.9.1. COMPANY OVERVIEW
    • 12.9.2. MISONIX, INC.-COMPANY SNAPSHOT
    • 12.9.3. PRODUCT PORTFOLIO
    • 12.9.4. RECENT DEVELOPMENTS (2013-2016)
  • 12.10. NEUWAVE MEDICAL, INC. (U.S) (ACQUIRED BY ETHICON-J&J GROUP OF COMPANY)
    • 12.10.1. COMPANY OVERVIEW
    • 12.10.2. PRODUCT PORTFOLIO
    • 12.10.3. RECENT DEVELOPMENTS (2013-2016)
  • 12.11. SONACARE MEDICAL, LLC (U.S)
    • 12.11.1. COMPANY OVERVIEW
    • 12.11.2. PRODUCT PORTFOLIO
    • 12.11.4. RECENT DEVELOPMENTS (2013-2016)

13. APPENDIX

  • 13.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE-1: GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION) UU
  • TABLE-2: TUMOR ABLATION MARKET SIZE FOR RF ABLATION TECHNOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-3: TUMOR ABLATION MARKET SIZE FOR MICROWAVE ABLATION TECHNOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-4: TUMOR ABLATION MARKET SIZE FOR CRYOABLATION TECHNOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-5: TUMOR ABLATION MARKET SIZE FOR OTHER TECHNOLOGIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-6: GLOBAL TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-7: CLINICAL PERSPECTIVE OF KEY HEPATOCELLULAR CARCINOMA SURGICAL TREATMENT MODES-A COMPARATIVE STUDY
  • TABLE-8: TUMOR ABLATION MARKET SIZE FOR SURGICAL MODE OF TREATMENT, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-9: TUMOR ABLATION MARKET SIZE FOR LAPAROSCOPIC MODE OF TREATMENT, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-10: TUMOR ABLATION MARKET SIZE FOR PERCUTANEOUS MODE OF TREATMENT, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-11: KEY PERCUTANEOUS TUMOR ABLATION TECHNOLOGIES-A COMPARATIVE STUDY
  • TABLE-12: GLOBAL TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-13: TUMOR ABLATION MARKET SIZE FOR LIVER CANCER APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-14: LIVER CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE-15: TUMOR ABLATION MARKET SIZE FOR LUNG CANCER APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-16: LUNG CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE-17: TUMOR ABLATION MARKET SIZE FOR KIDNEY CANCER APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-18: KIDNEY CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE-19: TUMOR ABLATION MARKET SIZE FOR BONE METASTASIS APPLICATION, Y REGION, 2014-2021 (USD MILLION)
  • TABLE-20: BONE METASTASIS ABLATION MARKET-INFLUENCING FACTORS
  • TABLE-21: TUMOR ABLATION MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-22: GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-23: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE-24: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-25: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-26: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-27: U.S.: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-28: U.S.: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-29: U.S.: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-30: CANADA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-31: CANADA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-32: CANADA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-33: EUROPE: TUMOR ABLATION MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE-34: EUROPE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-35: EUROPE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-36: EUROPE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-37: ITALY: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-38: ITALY: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-39: ITALY: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-40: GERMANY: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-41: GERMANY: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-42: GERMANY: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-43: FRANCE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014- 2021 (USD MILLION)
  • TABLE-44: FRANCE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-45: FRANCE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-46: U.K.: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-47: U.K.: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-48: U.K.: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-49: SPAIN: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-50: SPAIN: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-51: SPAIN: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-52: ROE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-53: ROE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-54: ROE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-55: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE-56: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-57: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-58: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-59: JAPAN: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-60: JAPAN: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-61: JAPAN: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-62: CHINA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-63: CHINA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-64: CHINA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-65: INDIA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-66: INDIA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-67: INDIA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-68: ROAPAC: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-69: ROAPAC: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-70: ROAPAC: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-71: ROW: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-72: ROW: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-73: ROW: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-74: PIPELINE DEVELOPMENTS AND PRODUCT ENHANCEMENTS (2013-2016)
  • TABLE-75: DIVESTMENTS AND ACQUISITIONS (2013-2016)
  • TABLE-76: GEOGRAPHIC EXPANSIONS (2013-2016)
  • TABLE-77: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2013-2016)
  • TABLE-78: OTHER DEVELOPMENTS (2013-2016)

LIST OF FIGURES

  • FIGURE-1: RESEARCH DESIGN
  • FIGURE-2: NUMBER OF NEW CANCER CASES, BY COUNTRY: 2012 VS. 2020
  • FIGURE-3: INCREASING INCIDENCES OF CANCERS, BY SITE: 2012-2020
  • FIGURE-4: INCREASE IN AGING POPULATION, BY COUNTRY: 2010 VS. 2015
  • FIGURE-5: PERCENTAGE INCREASE IN AGING POPULATION, BY REGION: (1980-2010) VS. (2010-2040)
  • FIGURE-6: HEALTHCARE EXPENDITURE ACROSS MAJOR COUNTRIES: 2000-2014
  • FIGURE-7: HEALTHCARE EXPENDITURE ACROSS MAJOR REGIONS: 2000-2014
  • FIGURE-8: SIGNIFICANT AVAILABILITY OF PUBLIC-PRIVATE INVESTMENTS TO SUPPORT TUMOR ABLATION-BASED RESEARCHES: LED BY U.S., CHINA AND EUROPE
  • FIGURE-9: TUMOR ABLATION IS EXPECTED TO BE THE FASTEST-GROWING ABLATION TECHNOLOGY APPLICATION SEGMENT TILL 2021
  • FIGURE-10: NUMBER OF NEW PRODUCT LAUNCHES: TUMOR ABLATION MARKET (2013-2016)
  • FIGURE-11: MARKET SIZE ESTIMATION
  • FIGURE-12: TUMOR ABLATION MARKET , BY COUNTRY/REGION (2016-2021)
  • FIGURE-13: TUMOR ABLATION MARKET: REGIONAL SCENARIO (2016)
  • FIGURE-14: GLOBAL TUMOR ABLATION MARKET FUTURE TRENDS, BY MODE OF TREATMENT AND APPLICATION (2016-2021)
  • FIGURE-15: GLOBAL PREVALENCE OF CANCER: EXPECTED TREND FOR 2012 VS. 2015 VS. 2020
  • FIGURE-16: KEY TUMOR ABLATION MARKETS: CHANGING PROPORTION OF GERIATRIC INDIVIDUALS IN THE TOTAL POPULATION (2012 VS. 2020)
  • FIGURE-17: PERCENTAGE CHANGE IN HEALTHCARE EXPENDITURE: DEVELOPED VS. DEVELOPING NATIONS (2005-2014)
  • FIGURE-18: TUMOR ABLATION MARKET, BY TECHNOLOGY: GROWTH FORECAST DURING 2016-2021
  • FIGURE-19: TUMOR ABLATION MARKET SHARE FOR RF TECHNOLOGY, BY REGION (2016)
  • FIGURE-20: TUMOR ABLATION MARKET SHARE FOR MICROWAVE TECHNOLOGY, BY REGION (2016)
  • FIGURE-21: TUMOR ABLATION MARKET SHARE FOR CRYOABLATION TECHNOLOGY, BY REGION (2016)
  • FIGURE-22: TUMOR ABLATION MARKET SHARE FOR OTHER TECHNOLOGIES, BY REGION (2016)
  • FIGURE-23: TUMOR ABLATION MARKET, BY MODE OF TREATMENT: GROWTH FORECAST DURING 2016-2021
  • FIGURE-24: TUMOR ABLATION MARKET FOR SURGICAL MODE OF TREATMENT, BY REGION (2016)
  • FIGURE-25: TUMOR ABLATION MARKET FOR LAPAROSCOPIC MODE, BY REGION (2016)
  • FIGURE-26: TUMOR ABLATION MARKET FOR PERCUTANEOUS MODE, BY REGION (2016)
  • FIGURE-27: TUMOR ABLATION MARKET, BY APPLICATION: GROWTH FORECAST DURING 2016-2021
  • FIGURE-28: TUMOR ABLATION MARKET SHARE FOR LIVER CANCER, BY REGION (2016)
  • FIGURE-29: TUMOR ABLATION MARKET SHARE FOR LUNG CANCER, BY REGION (2016)
  • FIGURE-30: TUMOR ABLATION MARKET SHARE FOR KIDNEY CANCER, BY REGION (2016)
  • FIGURE-31: TUMOR ABLATION MARKET SHARE FOR BONE METASTASIS, BY REGION (2016)
  • FIGURE-32: TUMOR ABLATION MARKET SHARE FOR OTHER APPLICATIONS, BY REGION (2016)
  • FIGURE-33: NORTH AMERICAN TUMOR ABLATION MARKET: EXPECTED TRENDS (2016 VS. 2021)
  • FIGURE-34: NORTH AMERICA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-35: U.S.: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-36: U.S.: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-37: U.S.: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-38: CANADA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-39: CANADA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-40: CANADA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-41: EUROPEAN TUMOR ABLATION MARKET: EXPECTED TRENDS (2016 VS. 2021)
  • FIGURE-42: EU5: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-43: ITALY: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-44: ITALY: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-45: ITALY: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-46: GERMANY: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-47: GERMANY: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-48: GERMANY: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-49: FRANCE: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-50: FRANCE: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-51: FRANCE: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-52: U.K.: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-53: U.K.: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-54: U.K.: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-55: SPAIN: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-56: SPAIN: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-57: SPAIN: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-58: ROE: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-59: ROE: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-60: ROE: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-61: ASIA-PACIFIC TUMOR ABLATION MARKET: EXPECTED TREND (2016 VS. 2021)
  • FIGURE-62: ASIA-PACIFIC: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-63: JAPAN: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-64: JAPAN: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-65: JAPAN: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-66: CHINA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-67: CHINA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-68: CHINA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-69: INDIA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-70: INDIA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-71: INDIA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-72: ROAPAC: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-73: ROAPAC: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-74: ROAPAC: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-75: ROW TUMOR ABLATION MARKET: EXPECTED TREND (2016 VS. 2021)
  • FIGURE-76: LEADING MARKET PLAYERS ADOPTED PRODUCT DEVELOPMENT AND COMMERCIALIZATION AS KEY GROWTH STRATEGIES DURING 2013-2016
  • FIGURE-77: TUMOR ABLATION MARKET SHARE, BY KEY PLAYER (2015)
  • FIGURE-78: KEY GROWTH STRATEGIES, BY YEAR (2013-2016)
  • FIGURE-79: PRODUCT DEVELOPMENT, THE MOST WIDELY ADOPTED GROWTH STRATEGY DURING 2013-2016
  • FIGURE-80: GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS: TUMOR ABLATION MARKET (2015)
  • FIGURE-81: PIPELINE DEVELOPMENT AND PRODUCT ENHANCEMENT IS THE KEY STRATEGY PURSUED BY TOP PLAYERS TO INCREASE THEIR TUMOR ABLATION MARKET REVENUE  
Back to Top